Answers are grounded in this paper and cite their sources.
A series of 4-aminoquinoline analogues and 4-aminoquinoline-benzoxaborole conjugates were synthesized and evaluated for their antiproliferative activities against two distinct breast cancer cell lines: MCF-7 (estrogen receptor-positive, ER+) and MDA-MB-231 (triple-negative). Preliminary dose-response assays revealed compound 5e, a 4-aminoquinoline-benzoxaborole conjugate, as the most active compound against MCF-7 cells. Structure-activity relationship (SAR) analysis indicated that the cytotoxic potency of the series increased with the length of the alkyl spacer connecting the pharmacophoric moieties. To assess selectivity, HEK-293 cells were employed as a non-cancerous control line, and most compounds exhibited minimal cytotoxicity, except compound 5d, which showed moderate effects. To gain preliminary structural insights, exploratory molecular docking studies were performed against the ligand-binding domain of estrogen receptor alpha (ERα). This integrated experimental-computational approach highlights the identification of promising preliminary hits. Overall, the findings show that 4-aminoquinoline-benzoxaborole conjugates exhibit antiproliferative activity against breast cancer cells, with greater potency towards MCF-7 cells.
No takes yet. Share an insight, caveat, or question.
Saini et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: